Subgroup analysis of the primary endpoints revealed no significant interactions among age, sex, duration of T2DM, glycated hemoglobin (HbA1c), BMI, history of CVD, or use of SGLT2 inhibitors (Figure 3). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.